Table 1 Selected clinical trials involving ARID1A in DDR and beyond; https://clinicaltrials.gov (accessed: 07.18.2022)
From: Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Target group | Clinical trial ID | Study title | Drug (target) | Disease | Study phase | Status |
|---|---|---|---|---|---|---|
Targeting DDR, ICB and combination | NCT02278250 | First in human study of M4344 in participants with advanced solid tumors | M4344 (ATRi) | Advanced solid tumors | 1 | Completed |
NCT03718091 | M6620 (VX-970) in selected solid tumors | M6620 (ATRi) | Solid tumor Leiomyosarcoma Osteosarcoma | 2 | Completed | |
NCT04042831 | Olaparib in treating patients with metastatic biliary tract cancer with aberrant DNA repair gene mutations | Olaparib (PARPi) | Biliary tract cancer | 2 | Recruiting | |
NCT03207347 | A trial of niraparib in BAP1 and other DNA damage response (DDR) deficient neoplasms (UF-STO-ETI-001) | Niraparib (PARPi) | Mesothelioma Uveal melanoma Renal cell Carcinoma Cholangiocarcinoma | 2 | Active, not recruiting | |
NCT04716686 | Niraparib monotherapy as maintain and recurrent treatment of endometrial serous carcinoma | Niraparib (PARPi) | Endometrial carcinoma Serous carcinoma | 2 | Recruiting | |
NCT04065269/ATARI | Atr inhibitor in combination with olaparib in gynecological cancers with arid1a loss or no loss | AZD6738 (ATRi) Olaparib (PARPi) | Gynecological cancers | 2 | Recruiting | |
NCT03682289 | Phase II trial of AZD6738 alone and in combination with olaparib | AZD6738 (ATRi) Olaparib (PARPi) | Advanced cancers | 2 | Recruiting | |
NCT02576444/OLAPCO | Olaparib combinations | AZD6738 (ATRi) AZD2281 (PARPi) AZD5363 (AKTi) AZD1775 (WEE1i) | Cancer | 2 | Active, not recruiting | |
NCT04633902 | Phase II study of olaparib and pembrolizumab in advanced melanoma with homologous recombination (HR) mutation | Olaparib (PARPi) Pembrolizumab (PD-1i) | Metastatic melanoma | 2 | Recruiting | |
NCT04953104 | Nivolumab for the treatment of patients with metastatic urothelial cancer with ARID1A mutation and stratify response based on CXCL13 expression | Nivolumab (PD-1i) | Urothelial cancer or solid tumors | 2 | Not yet recruiting | |
NCT04957615 | Nivolumab for the treatment of metastatic or unresectable solid tumors with ARID1A mutation and CXCL13 expression | Nivolumab (PD-1i) | Metastatic malignant solid neoplasm Unresectable solid neoplasm | 2 | Not yet recruiting | |
Targeting epigenetics, ICB and combination | NCT05154994/RESOLVE | Tremelimumab, durvalumab, and belinostat for the treatment of ARID1A mutated metastatic or unresectable, locally advanced urothelial carcinoma | Belinostat (HDACi) Durvalumab (PD-L1i) Tremelimumab (CTLA-4i) | Urothelial carcinoma | 1 | Recruiting |
NCT04493619 | PLX2853 as a single agent in advanced gynecological malignancies and in combination with carboplatin in platinum-resistant epithelial ovarian cancer | PLX2853 (BETi) Carboplatin | Gynecologic neoplasms | 1, 2 | Active, not recruiting | |
NCT03297424 | A Study of PLX2853 in Advanced Malignancies | PLX2853 (BETi) | Advanced malignancies | 1, 2 | Completed | |
NCT05023655 | Phase II study of tazemetostat in solid tumors harboring an ARID1A mutation | Tazemetostat (EZH2i) | Solid tumors | 2 | Recruiting | |
NCT03348631 | Tazemetostat in treating patients with recurrent ovarian or endometrial cancer | Tazemetostat (EZH2i) | Recurrent ovarian or endometrial cancer | 2 | Suspended | |
NCT04104776 | A study of CPI-0209 in patients with advanced solid tumors and lymphomas | CPI-0209 (EZH2i) | Advanced solid tumor and lymphomas | 1, 2 | Recruiting | |
Targeting kinases | NCT02059265 | Dasatinib in treating patients with recurrent or persistent ovarian, fallopian tube, endometrial or peritoneal cancer | Dasatinib (Multikinase inhibitor) | Recurrent gynecologic cancer | 2 | Active, not recruiting |
NCT01914510 | A study of ENMD-2076 in ovarian clear cell cancers | ENMD-2076 (Multikinase inhibitor) | Ovarian clear cell carcinoma | 2 | Completed |